rivaroxaban

Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and reduce the risk of blood clots. Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. It is taken by mouth.

In the Vinony graph

Vinony's link graph records 223 inbound references to rivaroxaban, and connects out to anticoagulant, pulmonary embolism and hirudin.

It is catalogued under topics including 2-Oxazolidinones, Chloroarenes and Direct Xa inhibitors.

Vinony links it to 31 Wikipedia language editions.

Key facts

Drug.pregnancy_AU: C
Drug.Verifiedfields: changed
Drug.verifiedrevid: 459434616
Drug.image: Rivaroxaban2DCSD.svg
Drug.image_class: skin-invert-image
Drug.width: 250
Drug.image2: Rivaroxaban xtal 2005.png
Drug.image_class2: bg-transparent
Drug.width2: 250
Drug.tradename: Xarelto, others
Drug.MedlinePlus: a611049
Drug.DailyMedID: Rivaroxaban
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: B01
Drug.ATC_suffix: AF01
Drug.legal_AU: S4
Drug.legal_CA: Rx-only
Drug.legal_UK: POM

via Wikipedia infobox

Chemical data

Formula: C19H18ClN3O5S
Molecular weight: 435.9 g/mol
IUPAC name: 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide
SMILES: C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl
InChIKey: KGFYHTZWPPHNLQ-AWEZNQCLSA-N
XLogP: 2.5
Polar surface area: 116 Å²
H-bond donors: 1
H-bond acceptors: 6
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 2008
Admin. routes: oral
Indications: atrial fibrillation, Venous thrombosis, deep vein thrombosis, venous thromboembolism

via ChEMBL · EBI

Research

10,063 papers

Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.Clinical pharmacokinetics · 2014
Rivaroxaban and the EINSTEIN clinical trial programme.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2019
Rivaroxaban for the treatment of venous thromboembolism in pediatric patients.Expert review of cardiovascular therapy · 2020
Rivaroxaban for treatment of livedoid vasculopathy: A systematic review.Dermatologic therapy · 2021
Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD.Drugs · 2020

via PubMed

Wikidata facts

Mass: 435.066
Has use: medication

Show 12 more facts

chemical formula: C₁₉H₁₈ClN₃O₅S
canonical SMILES: C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl
isomeric SMILES: C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl
defined daily dose: 20
World Health Organisation international non-proprietary name: rivaroxaban
Commons category: Rivaroxaban
subject has role: direct Xa inhibitor
medical condition treated: thrombophilia
physically interacts with: coagulation factor X
route of administration: oral administration
significant drug interaction: venlafaxine
legal status (medicine): boxed warning

Sources (7)

via Wikidata · CC0

~12 min read

Encyclopedic overview

13 sections

Contents

Medical uses
Contraindications
Adverse effects
Reversal agent
Mechanism of action
Chemistry
History
Society and culture
Economics
Legal status
Legal action
Research
References

{{Infobox drug | Verifiedfields = changed | verifiedrevid = 459434616 | image = Rivaroxaban2DCSD.svg | image_class = skin-invert-image | width = 250 | alt = | image2 = Rivaroxaban xtal 2005.png | image_class2 = bg-transparent | width2 = 250 | alt2 =

Excerpted from Wikipedia’s “rivaroxaban” article, available under the CC BY-SA 4.0 licence.